|
J Biol Chem, Vol. 275, Issue 16, 11852-11857, April 21, 2000
p300 and p300/cAMP-responsive Element-binding Protein Associated
Factor Interact with Human T-cell Lymphotropic Virus Type-1 Tax in a
Multi-histone Acetyltransferase/Activator-Enhancer Complex*
Robert
Harrod ,
Yu-Liang
Kuo ,
Yong
Tang ,
Yao
Yao ,
Alex
Vassilev§,
Yoshihiro
Nakatani§, and
Chou-Zen
Giam ¶
From the Department of Microbiology and Immunology,
Uniformed Services University of the Health Sciences, Bethesda,
Maryland 20814 and the § Laboratory of Molecular Growth
Regulation, NICHD, National Institutes of Health,
Bethesda, Maryland 20892-2753
 |
ABSTRACT |
The human T-cell lymphotropic virus, type
(HTLV)-1 trans-activator, Tax, coordinates with cAMP-responsive
element-binding protein (CREB) and the transcriptional co-activators
p300/CBP on three 21-base pair repeat elements in the proviral long
terminal repeat (LTR) to promote viral mRNA transcription.
Recruitment of p300/CBP to the activator-enhancer complex, however, is
insufficient to support Tax-dependent LTR trans-activation.
Here, we report that the p300/CBP-associated factor (P/CAF) is a
critical and integral component of the functional HTLV-1
activator-enhancer complex. The HTLV-1 Tax protein directly binds P/CAF
in vitro and co-immunoprecipitates with this co-activator
in vivo. The Tax mutants (K88A and V89A) defective for
p300/CBP-binding and LTR trans-activation, retained their abilities to
interact with P/CAF. The M47 mutant (L319R, L320S) protein, which has
previously been shown to interact with p300/CBP, by contrast, failed to
form complexes with P/CAF and is impaired in LTR trans-activation. Furthermore, LTR trans-activation by Tax is competitively inhibited by
the adenoviral E1A 12S gene product, which displaces P/CAF from
p300/CBP and inhibits the histone acetyltransferase activities of both
P/CAF and p300/CBP. This inhibition is partially reversed by
exogenously added P/CAF. These results imply that simultaneous recruitment of two distinct co-activators (p300/CBP and P/CAF) by Tax
is essential for the assembly of a trans-activation competent, nucleoprotein complex.
 |
INTRODUCTION |
The human T-cell lymphotropic virus, type-1
(HTLV-1),1 is the etiological
agent of adult T-cell leukemia/lymphoma and a neurodegenerative disorder, known as HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP 1-4). Viral infection leads to profoundly dysregulated cellular gene expression and concomitant T-cell
proliferation. The uncontrolled proliferative effects, as well as
neoplastic transformation by HTLV-1, are thought to be mediated by the
viral trans-activator Tax (5, 6). Numerous cellular transcription factors, including NF- B, SRF, AP-1, and CREB/ATF-1 family members, are aberrantly affected by Tax (7-22); effects on cell-cycle
regulatory molecules and certain tumor suppressors have also been
observed (23-29). HTLV-1 LTR trans-activation requires the assembly of
the 40-kDa trans-activator Tax and CREB/ATF-1 transcription factors on
three, 21-bp repeat enhancers located in the U3 region (22, 30-34).
Tax is known to directly interact with the basic domain leucine zipper
(bZip) of CREB/ATF-1, which binds the core cyclic AMP-responsive
element (CRE) in each 21-bp repeat (7, 13, 21, 35). Recent data suggest
that, upon binding to the basic domain of CREB bZip, Tax makes
additional contacts with the G/C-rich sequences that flank the CRE;
thus achieving the exquisite DNA sequence specificity of Tax-mediated
LTR trans-activation (35-38).
Kwok et al. (39) have shown that the co-activator,
CREB-binding protein (CBP), and its homologue, p300, directly bind to HTLV-1 Tax. We and others have confirmed and extended these results, and have demonstrated that amino acid residues 81-95 in Tax mediate its interaction with p300/CBP (40). Interestingly, the p300/CBP-binding region of Tax shares amino acid sequence similarity with residues comprising the kinase-inducible domain of CREB that undergoes Ca2+-dependent Ser-133 phosphorylation in
response to protein kinase A, MSK-1, or CAM-kinase IV activation
(40-44). Mutation, or deletion, of these residues abolishes the
ability of Tax to bind, or to form higher-order multiprotein complexes
with p300/CBP in vitro, and impairs
Tax-dependent trans-activation in vivo (40). We and others have also demonstrated that p300/CBP binding greatly stabilizes the activator-enhancer complex (39, 40, 45, 46). Interestingly, biochemical analyses of a well characterized Tax mutant,
M47, indicate that it retains the ability to interact with CREB, 21-bp
repeats, and p300/CBP, yet remains comparatively defective in
trans-activation of the HTLV-1 LTR (40, 47, 48). These results suggest
that recruitment of p300/CBP to the Tax/CREB/21-bp repeat complex is
necessary, but not sufficient, for Tax-dependent trans-activation. Thus, interactions between Tax and additional cellular co-activators or general transcription factors are likely to
be essential.
p300/CBP are general integrators of signal-dependent
transcription; a diverse array of enhancer-binding factors utilize
these co-activators for transcriptional activation in response to
extracellular stimuli (49-53). In addition to their role in
facilitating interactions between activators and components of the
basal transcription machinery, p300/CBP have been shown to possess
intrinsic histone acetyltransferase (HAT) activity (54). Remarkably,
another HAT, the p300/CBP-associated factor (P/CAF), has been shown to
directly interact with p300/CBP to form a multi-HAT/activator-enhancer
complex (55-57). The significance for the assembly of multiple-HATs on
enhancer elements is a subject of intense investigation. Interestingly,
the acetyltransferase activity of P/CAF is targeted toward histones H3
and H4 and appears to be redundant in light of similar activities of
p300/CBP (57, 58). It has previously been suggested that this
redundancy might reflect synergistic, or differential, HAT roles of
these co-activators on certain promoters (57-61). Here, we provide
evidence that recruitment of both p300/CBP and P/CAF by HTLV-1 Tax to
the activator-21-bp repeat enhancer complex is essential for efficient
LTR-dependent trans-activation. Moreover, we show that
Tax-mediated LTR trans-activation is competitively inhibited by
co-expressing the E1A 12S gene product, which inactivates both P/CAF
and p300/CBP (57, 62-66). Tax-derived mutants, defective for direct
interactions with either of these co-activators, in vitro
and in vivo, are similarly defective in their abilities to
activate transcription. These observations further imply that Tax might
influence nuclear P/CAF-containing complexes; thereby potentially
contributing to the pleiotropic dysregulated expression of numerous
cellular genes during leukemogenesis.
 |
EXPERIMENTAL PROCEDURES |
Transfections and Reporter Gene Assays--
HeLa cells (ATCC)
were plated at 2 × 105 cells/60-mm dish and cultured
for 24 h at 37 °C and 10% CO2 in Dulbecco's
modified Eagle's medium supplemented with 10% fetal bovine serum, 100 µg/ml streptomycin sulfate, and 100 units/ml penicillin (Life
Technologies, Inc.). These cells were washed twice with serum-free
medium and transfected using liposome-mediated DNA transfer
(LipofectAMINE reagent, Life Technologies, Inc.) as recommended by the
manufacturer. Briefly, the cells were incubated for 4 h with the
DNA/liposome mixtures; immediately following the incubation period, the
transfection solution was removed, cells were washed with serum-free
medium, and 2.5 ml of Dulbecco's modified Eagle's medium,
supplemented with 20% fetal bovine serum and 100 µg/ml streptomycin
sulfate, 100 units/ml penicillin, was added to each dish. The
transfected cells were incubated for another 48 h and harvested
for CAT-reporter assays by scraping, or extracted for
immunoprecipitation. To control for variation in transfection
efficiencies, cells were transfected in parallel with a CMV-lac Z
expression vector and stained with 5-bromo-4-chloro-3-indoyl
-D-galactoside for -galactosidase expression.
CAT-reporter assays were carried out as previously reported (40).
Results were quantified from triplicate experiments using an EAGLE-EYE
II Video-imaging system (Stratagene, Inc.).
Co-immunoprecipitations and Western
Blotting--
Co-immunoprecipitations were carried out using extracts
prepared from HeLa cells, transfected as described with a CMV-driven, FLAG epitope-tagged (f)P/CAF expression vector and either a CMV-driven wild-type or mutant, Tax expression plasmid. Transfected cells were
harvested by scraping, washed three times with phosphate-buffered saline, and lysed in 500 µl of RIPA buffer (0.15 M NaCl,
50 mM Tris-Cl, pH 7.4, 0.5% sodium deoxycholate, 0.5%
Nonidet P-40, 0.1% SDS), containing 50 ng/ml each of the protease
inhibitors, pepstatin, leupeptin, chymostatin, bestatin,
antipain-dihydrochloride (Roche Molecular Biochemicals), by repeated
passage through a 27.5-gauge syringe. Cell debris was removed by
centrifugation at 12,000 rpm for 10 min at 4 °C. Two-hundred and
fifty microliters from each sample was used for immunoprecipitation.
Lysates were precleared by incubation with either 20 µl of a 50%
slurry of Protein A- (Pierce, Inc.) or Protein G-agarose (Life
Technologies, Inc.) and 5 µl of antiserum for 30 min at 4 °C,
followed by brief centrifugation at 1200 rpm for 5 min. After
preclearing, either 100 µl of an anti-Tax, monoclonal antibody (4C5)
against a C-terminal epitope (located after residue 324) in
Tax,2 or 10 µl of
anti-FLAG-M2, mouse monoclonal antibody (Eastman-Kodak Corp.), were
added to each sample. The reactions were preincubated at 4 °C for
1 h; then, 100 µl of either protein A-agarose, or Protein
G-agarose, were added to reactions containing anti-Tax or anti-FLAG-M2
antibodies, respectively, and further incubated overnight. On the
following day, immune complexes were pelleted by centrifugation at 1200 rpm for 5 min at 4 °C, washed three times with 500 µl of RIPA
buffer containing the above mentioned protease inhibitors, and
resuspended in 30 µl of SDS-PAGE loading buffer. Samples were heated
to 95 °C for 3 min, centrifuged, and 15 µl from each were loaded
on a 12.5% SDS-polyacrylamide gel containing a 4% stacking gel.
Electrophoresis was carried out at 150 V/150 mAmps using a 0.25 M Tris, 0.19 M glycine, 0.1% SDS running
buffer; gels were transferred through a 10 mM CAPS, pH 11.0, 10% (v/v) methanol buffer to nitrocellulose membranes
(Schleicher and Schuell, Inc.), and used for immunoblotting by standard
protocols. For detection of (f)P/CAF expression, blots were incubated
for 2 h with anti-FLAG-M2 antibody (diluted 1:1000), washed twice with BLOTTO buffer (50 mM Tris-HCl, pH 8.0, 2 mM CaCl2, 80 mM NaCl, 0.2% (v/v)
Nonidet P-40, 0.02% (w/v) sodium azide, 5% nonfat dry milk),
incubated for 1 h in an anti-mouse horseradish
peroxidase-conjugated, secondary antibody (diluted 1:1000, Santa Cruz
Biotechnology, Inc.), washed twice with BLOTTO, and once again with
phosphate-buffered saline, and developed using a chemiluminescent
substrate (SuperSignal, Pierce, Inc.). For detection of HTLV-1 Tax, or
Tax-derived mutant proteins, the nitrocellulose membranes were probed
with the anti-Tax monoclonal antibody (diluted 1:20) and immunoblotted
as described. X-ray film was briefly exposed for autoradiography as
previously mentioned. Alternatively, co-immunoprecipitations were
performed using extracts prepared either from Jurkat and HTLV-1
transformed cell-lines (MT-4 and C8166), or JPX-9 cells, which express
a metal-inducible version of wild-type Tax, induced for 12 h with
0, 1.5, 15, or 30 µM CdCl2 in RPMI medium
supplemented with 20% fetal bovine serum and 100 µg/ml streptomycin
sulfate and 100 units/ml penicillin (Life Technologies, Inc.) in the
presence of 10% CO2. Extracts were prepared and treated as
described previously, with the exception that immunoprecipitations were
performed using 5 µl of a goat polyclonal, anti-P/CAF antibody (Santa
Cruz Biotechnology, Inc.), and Tax was detected in P/CAF-containing
complexes by Western blotting.
Plasmid Constructions and Protein Purification--
The RcCMV
plasmid, CMV-(f)P/CAF, CMV-E1A 12S, CMV-E1A 12S N, CMV-HTLV-1 Tax
expression vectors, the CMV-driven expression vectors for the
Tax-derived mutants, M47, K88A, and V89A, 218-CAT reporter plasmid,
GST-HTLV-1 Tax, and GST-M47 vectors have all been previously described
(22, 40, 47, 57, 67). pGEX-2T is from Amersham Pharmacia Biotech; and
CMV-lac Z is from Life Technologies, Inc. GST-K88A and
GST-V89A were constructed in GST-Tax by replacing the wild-type Tax
coding sequence with those of the respective alanine substitution
mutants (22, 40). GST fusion proteins were expressed and purified as
prescribed by standard protocols. The purification of HTLV-1 Tax-His,
or M47-His6, K88A-His6, and V89A-His6 have been previously described
(22, 35, 40, 48, 67). Purification protocols for baculovirus-expressed p300 and FLAG epitope-tagged (f)P/CAF have likewise been reported elsewhere (54, 57).
Glutathione S-Transferase Binding Assays and in Vitro Complex
Formation--
To examine the possibility that HTLV-1 Tax and P/CAF
might directly interact, 0.5-1 µg of purified GST or GST-Tax fusion
protein (or an equivalent amount of each GST-Tax mutant protein) was
pre-immobilized on 60 µl of a 50% slurry of washed
glutathione-Sepharose 4B (Amersham Pharmacia Biotech) in 200 µl of
1 × binding buffer (25 mM Hepes, pH 7.9, 5 mM KCl, 0.5 mM MgCl2, 0.5 mM EDTA, 1 mg/ml bovine serum albumin, 10% (v/v) glycerol,
0.25 mM dithiothreitol) on ice for 2 h. The bound
matrices were washed twice with 500 µl of 1 × binding buffer,
pelleted by centrifugation at 1200 rpm for 5 min, and resuspended in 30 µl of 1 × binding buffer. Purified, FLAG epitope-tagged (f)PCAF
(0.2-0.5 µg) was added to each binding reaction and samples were
incubated for 30 min, with agitation, at room temperature. Following
incubation, the bound matrices were washed three times with 500 µl of
1 × binding buffer and pelleted by centrifugation, resuspended in
30 µl of SDS-PAGE loading buffer, heated to 95 °C, and 15 µl
from each reaction were analyzed by 12.5% SDS-PAGE and immunoblotting,
as described.
To examine the recruitment of P/CAF and p300 by HTLV-1 Tax into a
multiprotein complex bound to the 21-bp repeat DNA, we labeled 1 µg
of the annealed oligonucleotides:
5'-GATCTGGGCGTTGACGACAACCCCTCACCTCAAAAAACTTTC-3' and
5'-TTTGAAAGTTTTTTGAGGTGAGGGGTTGTCGTCAACGCCCAGATC-3' (HTLV-1
21-bp repeat sequence is shown in bold), with biotin-14-dATP (Life
Technologies, Inc.) using 7.5 units of Klenow (New England Biolabs,
Inc.) at 37 °C for 30 min. Labeled oligonucleotides were electrophoresed and purified from a 7.5% TBE (Tris borate/EDTA) acrylamide gel, eluted in 250 µl of deionized dH2O,
quantified, and 10 µl (20 ng) were used in each binding reaction.
Sixty microliters of a 50% slurry of washed, streptavidin-agarose
(Life Technologies, Inc.) were mixed with 20 ng of biotinylated
oligonucleotide in 200 µl of 1 × binding buffer (see above) and
preincubated on ice for 2 h. The bound matrices were washed twice
with 500 µl of 1 × binding buffer, pelleted by centrifugation,
and resuspended in a total reaction volume of 50 µl (1 × binding buffer). One microgram of purified CREB bZip, 200 ng of HTLV-1
Tax-His6 (or Tax-derived mutant), 500 ng of baculovirus-expressed p300,
and 500 ng of (f)P/CAF was added to each binding reaction and incubated at room temperature, with agitation for 30 min. Following incubation, the matrices were washed three times (5 min each) with 500 µl of
1 × binding buffer, pelleted, and resuspended in 40 µl of
SDS-PAGE loading buffer. Ten microliters from each sample were heated
at 95 °C for 3 min and loaded either on a 12.5% SDS-polyacrylamide gel, or a pre-cast 4-20% Tris glycine acrylamide gel (Novex, Inc.), for resolution of bound products. After electrophoresis, the gels were
either transferred to nitrocellulose membranes for immunoblotting (Tax,
P/CAF, p300) as described, or stained with Coomassie Blue reagent for
direct visualization (CREB bZip). Purified p300 was detected using a
monoclonal anti-p300 antibody (diluted 1:1000, Upstate Biotechnology,
Inc.); P/CAF was detected using a goat anti-P/CAF polyclonal antibody
(diluted 1:1000, Santa Cruz Biotechnology, Inc.), and an horseradish
peroxidase-conjugated anti-goat secondary antibody (diluted 1:1000,
Santa Cruz Biotechnology, Inc.).
 |
RESULTS |
E1A 12S Inhibition of Tax-dependent LTR
Trans-activation--
We have previously shown that the recruitment of
p300/CBP alone by HTLV-1 Tax is necessary but not sufficient for
optimal trans-activation. In this study, we examine the role of the
co-activator/histone acetyltransferase, P/CAF, and its cooperation with
p300/CBP in Tax-mediated trans-activation from the HTLV-1 LTR. It is
well documented that P/CAF and the adenoviral E1A 12S protein share overlapping binding sites on the co-activator p300/CBP (Fig.
1A) (57, 59, 63, 65), and E1A
12S directly binds P/CAF and inhibits its transcription function (66).
It is, therefore, possible that E1A 12S might negatively affect
Tax-dependent trans-activation of a CAT reporter whose
expression is driven by the two promoter-proximal 21-bp repeats of the
HTLV-1 LTR. As shown in Fig. 1B, Tax-mediated trans-activation of a (×2) 21-bp repeat-CAT-reporter gene (218-CAT) was inhibited in the presence of increasing concentrations of a CMV-E1A
12S expression vector while the control RcCMV vector had no effect on
Tax trans-activation. A vector that expressed a mutant form of E1A 12S,
CMV-E1A 12S N, which lacks N-terminal amino acid residues necessary
for its interaction with p300/CBP, did not significantly inhibit
Tax-mediated trans-activation when transfected at levels comparable to
that of the wild-type E1A 12S expression plasmid (Fig. 1C).
These data are consistent with previous reports on E1A 12S inhibition
of P/CAF-dependent transcription and further implicate
P/CAF as an essential member of the functional activator-enhancer
complex on the HTLV-1 21-bp repeats (57, 59, 63, 65, 66).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
P/CAF and adenoviral E1A 12S share
overlapping docking sites on the co-activator CBP. A,
diagram showing binding sites for E1A 12S and P/CAF (57, 59, 63, 65).
B, Tax-dependent HTLV-1 LTR trans-activation is
competitively inhibited by E1A 12S expression. HeLa cells were
co-transfected with a 218-CAT reporter plasmid (1 µg), RcCMV empty
vector, CMV-Tax (1.5 µg) and CMV-E1A 12S (0.5, 1, 2, and 3 µg)
expression constructs; cells were harvested and chloramphenicol
acetyltransferase activities were determined by radioisotopic assays.
C, an E1A 12S mutant lacking the p300-interacting domain
failed to compete against HTLV-1 LTR trans-activation. HeLa cells were
transfected as described, with the exception that a mutant E1A 12S
expression construct, CMV-E1A 12S N, was used (1, 2, and 3 µg).
D, E1A 12S-competition of Tax-dependent LTR
trans-activation is partially blocked by increasing intracellular
P/CAF. HeLa cells were co-transfected with a 218-CAT reporter plasmid
(1 µg), CMV-E1A 12S (3 µg), and CMV-Tax (1.5 µg) expression
constructs. Increasing concentrations of a CMV-(f)P/CAF expression
vector (0.5, 1.5, and 3 µg) were also included in certain reactions.
Following 48 h incubation, cells were harvested, lysates prepared,
protein concentrations quantified, and radioisotopic CAT assays were
performed.
|
|
P/CAF Co-expression Partially Reverses E1A 12S Inhibitory
Effects--
To address whether E1A 12S inhibition of
Tax-dependent LTR trans-activation occurs due to E1A 12S
inactivation of a limiting pool of P/CAF, we attempted to reverse the
E1A 12S inhibitory effect by exogenously increasing P/CAF expression.
An inhibitory level of a CMV-E1A 12S expression vector was
co-transfected with CMV-Tax and 218-CAT; a CMV-(f)P/CAF construct was
included at progressively increasing concentrations in transfections.
As shown in Fig. 1D, E1A 12S strongly inhibited Tax-mediated
trans-activation from the 21-bp repeats, whereas, CMV-(f)P/CAF alone
did not significantly affect basal, or Tax-dependent,
reporter gene expression. Notably, E1A 12S inhibition was partially
prevented by increasing the intracellular pool of (f)P/CAF. A complete
restoration of Tax-dependent trans-activation, however,
could not be achieved, even with relatively high CMV-(f)P/CAF concentrations. This is consistent with reports by others of a multi-level E1A 12S inhibitory effect on transcription (59, 63, 65,
66). These data, collectively, are in agreement with the notions that
P/CAF is a nuclear factor that is essential for HTLV-1 21-bp repeat
trans-activation.
Analyses of Tax-P/CAF Complexes by Immunoprecipitation and GST
Pull-down--
In order to observe potential Tax-P/CAF interactions
in vivo, HeLa cells were co-transfected either with a CMV
wild-type, or mutant, Tax expression vector and CMV-(f)P/CAF, which
expresses FLAG epitope-tagged P/CAF. Whole cell extracts were prepared
as described and immunoprecipitation was performed using either an anti-FLAG-M2 antibody (Eastman-Kodak Corp.) or an anti-Tax monoclonal antibody. Immunoblotting results revealed that the wild-type Tax protein, as well as the CBP-binding defective mutants K88A and V89A,
co-immunoprecipitated with (f)P/CAF using either the anti-FLAG-M2 antibody (Fig. 2A, middle panel,
lanes 3, 5, and 6) or anti-Tax antibody (Fig. 2A,
lower panel, lanes 3, 5, and 6). In contrast, the M47
mutant of Tax only weakly immunoprecipitated in complexes that
contained (f)P/CAF (Fig. 2A, top and middle panels,
lane 4 of each). The minute but detectable amount of
immunoprecipitated M47 most likely represents M47 indirectly complexed
with (f)P/CAF through binding p300/CBP. Approximately equivalent
amounts of wild-type, or mutant, Tax proteins and (f)P/CAF were
expressed in transfected cells (Fig. 2A, top panel, and data
not shown, respectively). To detect Tax-P/CAF interactions in
Tax-expressing lymphoid-derived cells, JPX-9 cells were induced by
treatment with increasing concentrations of CdCl2 for
12 h; extracts were prepared and immunoprecipitation was performed
as described (68). Upon induction, Tax was detectable in
P/CAF-containing immune complexes in a dose-dependent
manner (Fig. 2B, top panel). In addition, Tax could also be
immunoprecipitated with P/CAF in extracts prepared from
HTLV-1-transformed cells (Fig. 2B, bottom panel). The
presence of approximately equivalent amounts of P/CAF in these immunoprecipitates was verified by Western blotting (data not shown).
These results suggest that HTLV-1 Tax most likely complexes directly
with P/CAF.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Wild-type Tax and mutants K88A and V89A
interact with P/CAF in immunoprecipitation and GST pull-down
experiments. A, HeLa cells were co-transfected with
CMV-(f)P/CAF (2 µg), and RcCMV empty vector, CMV-WT Tax, CMV-M47,
CMV-K88A, or CMV-V89A (1.5 µg) as described. Cells were lysed and
immunoprecipitation was performed as described under "Experimental
Procedures." B, Tax is detectable in P/CAF immunocomplexes
isolated from Tax-expressing lymphoid cells. Extracts were prepared
from JPX-9 cells, treated with increasing concentrations of
CdCl2 to induce Tax expression, or from Jurkat and HTLV-1
transformed cell-lines (MT-4; C8166). Immunoprecipitations were
performed as described under "Experimental Procedures."
C, HTLV-1 Tax and p300/CBP-binding defective, Tax-derived
mutants interact with (f)P/CAF in GST pull-down assays. Bound (f)P/CAF,
following GST pull-down assays, was determined by immunoblotting using
anti-FLAG-M2 antibody as described. One-third of the input (f)P/CAF is
shown in the far left lane.
|
|
In an effort to biochemically analyze Tax-P/CAF interactions in
vitro, GST pull-down assays were performed using purified (f)P/CAF
and immobilized GST wild-type, or mutant, Tax proteins. As shown in
Fig. 2C, GST-Tax, GST-K88A, and GST-V89A all displayed efficient binding to (f)P/CAF. The GST-M47 protein, however, did not
show a significant interaction with (f)P/CAF; neither did the matrix
alone or GST control. Input levels of purified GST or GST-Tax fusion
proteins were comparable as determined by SDS-PAGE and Coomassie
staining. Again, in this assay, the M47 mutant of Tax is defective in
its ability to interact with P/CAF in vitro; reflective of
data obtained from immunoprecipitations and transfection experiments as
described earlier. Of note, P/CAF co-expression could not significantly
restore the trans-activation defect observed for M47 in vivo
(data not shown).
Assembly of a Multi-HAT/Activator-Enhancer Complex--
In order
to study the recruitment of P/CAF, as well as p300/CBP, by HTLV-1 Tax
on the 21-bp repeat, in vitro, we formed multiprotein complexes in the presence of purified CREB bZip on immobilized, biotin-labeled 21-bp repeat oligonucleotides. As shown in Fig. 3, approximately equivalent amounts of
CREB bZip and biotinylated-DNA were eluted from each reaction.
Likewise, similar amounts of HTLV-1 Tax, or Tax-derived mutants M47,
K88A, and V89A, were observed in complete binding reactions
(lanes 3-6). No significant complex formation was observed
in the negative controls, either in the absence of CREB bZip
(lane 1) or Tax (lane 2). Consistent with previously published data, only wild-type Tax and M47 significantly interacted with purified p300 in multiprotein complexes on the 21-bp
repeat DNA (lanes 3 and 4). Interestingly, P/CAF
binding was observed only in complete binding reactions that contained wild-type Tax, K88A, or V89A (lanes 3, 5, and 6).
These results are in agreement with those obtained from
co-immunoprecipitation and GST pull-down experiments, and further
confirm the hypothesis that HTLV-1 Tax interacts directly with both
P/CAF and p300/CBP in a multi-coactivator/activator-enhancer complex.
Of significance, the M47 mutant (lane 4) did not exhibit
higher order complex formation with P/CAF, even though its recruitment
of p300/CBP appeared not to be impaired; thus, the p300-P/CAF
interaction appeared weak under our assay conditions, requiring Tax to
further stabilize multiple protein contacts.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Assembly of a multi-HAT/activator-enhancer
complex. A, CREB bZip, Tax, or Tax-derived mutants,
p300, and P/CAF proteins were incubated with a biotinylated 21-bp
repeat DNA probe. Streptavidin-agarose affinity matrices were used to
isolate bound components. After washing, bound factors were resolved by
SDS-PAGE and visualized either by Coomassie staining or immunoblotting
as described. B, model of interactions between Tax and
p300-P/CAF on an HTLV-1 21-bp repeat element.
|
|
V89A and M47 Exhibit Trans-complementation Properties--
The
importance of both p300/CBP and P/CAF interactions in Tax-mediated
trans-activation is further suggested by the trans-complementation effect of the V89A mutant, which is defective in p300/CBP binding, on
the trans-activation activity of M47, a mutant shown here to be
defective in P/CAF binding. As shown in Fig.
4, V89A and M47 mutants each exhibited
residual trans-activation activities. Co-expression of V89A and M47
partially restored the trans-activation activity of each mutant in a
dose-dependent manner, possibly through the formation of a
partially active M47/V89A heterodimer, as suggested by the molar ratios
for optimal trans-activation. Furthermore, their combined effect
appeared to be synergistic. These data are suggestive that a tripartite
interaction between Tax, p300/CBP, and P/CAF, together with CREB dimer
bound to the 21-bp repeat element, might be required in order for
Tax-mediated LTR trans-activation to occur (Fig. 3B).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 4.
The V89A and M47 Tax mutants exhibit
synergistic trans-complementation. HeLa cells were co-transfected
with a 218-CAT reporter plasmid (1 µg), CMV-Tax (1.5 µg), CMV-M47
(1.5, 1.25, 1.0, 0.75, 0.5, or 0.25 µg), and/or CMV-V89A expression
constructs (1.5, 1.25, 1.0, 0.75, 0.5, or 0.25 µg). Cells were
cultured, lysates were prepared, and CAT assays were performed and
quantified as described.
|
|
 |
DISCUSSION |
With this study, we have demonstrated that both P/CAF and p300/CBP
directly interact with HTLV-1 Tax. Immune complexes containing P/CAF
and Tax were readily detectable in extracts prepared either from
induced JPX-9 cells or HTLV-1 transformed cell lines. Recruitment of
both co-activators is required for Tax-mediated trans-activation from
the HTLV-1 enhancer. P/CAF is a co-activator/HAT that has been shown to
recognize a domain in p300/CBP that also interacts with the adenoviral
E1A 12S protein (57, 59, 63, 65). Indeed, E1A 12S has been reported to
competitively inhibit the function of activators, such as Stat-1a, by
displacing P/CAF from p300/CBP (59, 60). Recently, others have also
demonstrated that the E1A 12S protein can directly inhibit
P/CAF-dependent activation (66). Consistent with the
function of P/CAF as a key co-activator/HAT in specific enhancer
complexes that contain p300/CBP, Tax-mediated LTR trans-activation was
competitively inhibited by co-expression of E1A 12S. This inhibition
was, at least partially, prevented by increasing the intracellular
concentration of P/CAF. That a complete reversal of E1A 12S inhibition
was not achieved is consistent with a multilevel inhibitory effect of P/CAF function by E1A 12S as proposed by others (59, 63, 66).
Although p300/CBP have been shown to directly bind P/CAF (57, 59), in
our in vitro assays, the presence of Tax is critical for the
recruitment of both p300/CBP and P/CAF, respectively. The M47 mutant,
which efficiently interacts with p300/CBP, did not show a detectable
interaction with P/CAF. The Tax mutants K88A and V89A, which were
previously characterized as being defective for p300/CBP binding (40),
were able to interact with P/CAF but unable to bind p300 in the
biotin-21-bp repeat pull-down experiments. Thus, the p300/CBP-P/CAF
interaction might be relatively weak under the conditions of our assay,
and requires Tax to further stabilize protein contacts. The
implications from these results may extend to promoter elements of
other genes where multiple activator/co-activator interactions are
needed to drive transcriptional activation. As both classes of Tax
mutants, M47 and K88A/V89A, defective for P/CAF and p300/CBP binding,
respectively, are impaired, but not completely abrogated, in their
abilities to activate LTR-dependent transcription (40, 47),
these data support the notion that recruitment of both types of
co-activators to the HTLV-1 21-bp repeat by Tax is necessary for
optimal trans-activation. Consistent with this hypothesis, P/CAF
co-immunoprecipitated with wild-type Tax, as well as with
p300/CBP-binding defective Tax mutants; likewise similar binding was
observed in GST pull-down experiments in vitro. Conversely,
M47, which interacts with p300/CBP with an affinity comparable to that
observed for the wild-type Tax protein (40), neither exhibited
significant interaction with P/CAF in immunoprecipitations, nor in GST
pull-down experiments.
p300/CBP and P/CAF have previously been shown to possess histone and
protein acetyltransferase activities (54, 57, 58). In addition, these
proteins are known to interact with an increasing array of activators
and general transcription factors (49-51). It is possible that the
major function of p300/CBP and P/CAF, upon their recruitment by Tax to
the viral enhancer, is to modify histones to release the HTLV-1
promoter from the suppressive effects of chromatin architecture.
Therefore, the interaction of HTLV-1 Tax with two distinct co-activator
molecules might reflect a requirement for dual-HATs to remodel
chromatin at the 21-bp repeat element via multistep, and possibly
multisite, nucleosomal acetylation. Alternatively, P/CAF and p300/CBP
may act at separate stages of transcription. Indeed, p300 is known to
directly bind RNA polymerase II, whereas, P/CAF has been shown to
interact only with the hyper-phosphorylated, elongation-competent form
of the polymerase (69). It remains to be determined at precisely which
stage, initiation or elongation, the trans-activation defects for M47
and K88A/V89A reside. Our present study suggests that interactions
between Tax and other components of the cellular co-activator network,
or basal transcription machinery, are likely to be necessary for
efficient Tax-mediated LTR trans-activation.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Mark Glover (University of
Alberta) for generously providing the purified CREB bZip protein used
in this study. We also thank Charnita Whitmyer for technical
assistance, and other members of the Giam lab for helpful discussions
and critical reading of the manuscript.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants RO1 CA48709 and RO1 CA/GM 75688.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
301-295-9624; Fax: 301-295-1545; E-mail:
giam@bob.usuf2.usuhs.mil.
2
Y. Yao, Y-L. Kuo, Y. Tang, R. Harrod, C. Broder,
W. Harrington, and C-Z. Giam, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
HTLV-1, human T-cell
lymphotropic virus type-1;
CRE, cyclic AMP-responsive element;
ATF-1, activating transcription factor-1;
CREB, CRE-binding protein;
CBP, CREB-binding protein;
P/CAF, p300/CBP-associated factor;
HAT, histone
acetyltransferase;
CAT, chloramphenicol acetyltransferase;
CMV, cytomegalovirus;
PAGE, polyacrylamide gel electrophoresis;
LTR, long
terminal repeat;
bp, base pair(s);
CAPS, 3-(cyclohexylamino)propanesulfonic acid.
 |
REFERENCES |
| 1.
|
Gessain, A.,
Barin, F.,
Vernant, J. C.,
Gout, O.,
Maurs, L.,
Calender, A.,
and de The, G.
(1985)
Lancet
2,
407-410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Osame, M.,
Matsumoto, M.,
Usuku, K.,
Izumo, S.,
Ijichi, N.,
Amitani, H.,
Tara, M.,
and Igata, A.
(1987)
Ann. Neurol.
21,
117-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Poiesz, B. J.,
Ruscetti, F. W.,
Gazdar, A. F.,
Bunn, P. A.,
Minna, J. D.,
and Gallo, R. C.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
7415-7419[Abstract/Free Full Text]
|
| 4.
|
Yoshida, M.,
Miyoshi, I.,
and Hinuma, Y.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
2031-2035[Abstract/Free Full Text]
|
| 5.
|
Tanaka, A.,
Takahashi, C.,
Yamaoka, S.,
Nosaka, T.,
Maki, M.,
and Hatanaka, M.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
1071-1075[Abstract/Free Full Text]
|
| 6.
|
Yamaoka, S.,
Tobe, T.,
and Hatanaka, M.
(1992)
Oncogene
7,
433-437[Medline]
[Order article via Infotrieve]
|
| 7.
|
Adya, N.,
Zhao, L. J.,
Huang, W.,
Boros, I.,
and Giam, C. Z.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
5642-5646[Abstract/Free Full Text]
|
| 8.
|
Bantignies, F.,
Rousset, R.,
Desbois, C.,
and Jalinot, P.
(1996)
Mol. Cell. Biol.
16,
2174-2182[Abstract]
|
| 9.
|
Curtiss, V. E.,
Smilde, R.,
and McGuire, K. L.
(1996)
Mol. Cell. Biol.
16,
3567-3575[Abstract]
|
| 10.
|
Fujii, M.,
Chuhjo, T.,
Minamino, T.,
Masaaki, N.,
Miyamoto, K.,
and Seiki, M.
(1995)
Oncogene
11,
7-14[Medline]
[Order article via Infotrieve]
|
| 11.
|
Kanno, T.,
Franzoso, G.,
and Siebenlist, U.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
12634-12638[Abstract/Free Full Text]
|
| 12.
|
Nicot, C.,
Tie, F.,
and Giam, C. Z.
(1998)
J. Virol.
72,
6777-6784[Abstract/Free Full Text]
|
| 13.
|
Perini, G.,
Wagner, S.,
and Green, M. R.
(1995)
Nature
376,
602-605[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Shnyreva, M.,
and Munder, T.
(1996)
J. Virol.
70,
7478-7484[Abstract]
|
| 15.
|
Sun, S. C.,
Elwood, J.,
Beraud, C.,
and Greene, W. C.
(1994)
Mol. Cell. Biol.
14,
7377-7384[Abstract/Free Full Text]
|
| 16.
|
Suzuki, T.,
Hirai, H.,
Fujisawa, J.,
Fujita, T.,
and Yoshida, M.
(1993)
Oncogene
8,
2391-2397[Medline]
[Order article via Infotrieve]
|
| 17.
|
Suzuki, T.,
Hirai, H.,
Murakami, T.,
and Yoshida, M.
(1995)
Oncogene
10,
1199-1207[Medline]
[Order article via Infotrieve]
|
| 18.
|
Yamagata, T.,
Mitani, K.,
Ueno, H.,
Kanda, Y.,
Yazaki, Y.,
and Hirai, H.
(1997)
Mol. Cell. Biol.
17,
4272-4281[Abstract]
|
| 19.
|
Yamaoka, S.,
Inoue, H.,
Sakurai, M.,
Sugiyama, T.,
Hazama, M.,
Yamada, T.,
and Hatanaka, M.
(1996)
EMBO J.
15,
873-887[Medline]
[Order article via Infotrieve]
|
| 20.
|
Yin, M. J.,
Christerson, L. B.,
Yamamoto, Y.,
Kwak, Y. T.,
Xu, S.,
Mercurio, F.,
Barbosa, M.,
Cobb, M. H.,
and Gaynor, R. B.
(1998)
Cell
93,
875-884[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Yin, M. J.,
Paulssen, E. J.,
Seeler, J. S.,
and Gaynor, R. B.
(1995)
J. Virol.
69,
3420-3432[Abstract]
|
| 22.
|
Zhao, L. J.,
and Giam, C. Z.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
7070-7074[Abstract/Free Full Text]
|
| 23.
|
Akagi, T.,
Ono, H.,
and Shimotohno, K.
(1996)
Oncogene
12,
1645-1652[Medline]
[Order article via Infotrieve]
|
| 24.
|
Cereseto, A.,
Diella, F.,
Mulloy, J. C.,
Cara, A.,
Michieli, P.,
Grassmann, R.,
Franchini, G.,
and Klotman, M. E.
(1996)
Blood
88,
1551-1560[Abstract/Free Full Text]
|
| 25.
|
Jin, D. Y.,
Spencer, F.,
and Jeang, K. T.
(1998)
Cell
93,
81-91[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Mulloy, J. C.,
Kislyakova, T.,
Cereseto, A.,
Casareto, L.,
LoMonico, A.,
Fullen, J.,
Lorenzi, M. V.,
Cara, A.,
Nicot, C.,
Giam, C.,
and Franchini, G.
(1998)
J. Virol.
72,
8852-8860[Abstract/Free Full Text]
|
| 27.
|
Neuveut, C.,
Low, K. G.,
Maldarelli, F.,
Schmitt, I.,
Majone, F.,
Grassmann, R.,
and Jeang, K. T.
(1998)
Mol. Cell. Biol.
18,
3620-3632[Abstract/Free Full Text]
|
| 28.
|
Suzuki, T.,
Kitao, S.,
Matsushime, H.,
and Yoshida, M.
(1996)
EMBO J.
15,
1607-1614[Medline]
[Order article via Infotrieve]
|
| 29.
|
Uittenbogaard, M. N.,
Giebler, H. A.,
Reisman, D.,
and Nyborg, J. K.
(1995)
J. Biol. Chem.
270,
28503-28506[Abstract/Free Full Text]
|
| 30.
|
Paca Uccaralertkun, S.,
Zhao, L. J.,
Adya, N.,
Cross, J. V.,
Cullen, B. R.,
Boros, I. M.,
and Giam, C. Z.
(1994)
Mol. Cell. Biol.
14,
456-462[Abstract/Free Full Text]
|
| 31.
|
Suzuki, T.,
Fujisawa, J. I.,
Toita, M.,
and Yoshida, M.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
610-614[Abstract/Free Full Text]
|
| 32.
|
Yin, M. J.,
and Gaynor, R. B.
(1996)
Mol. Cell. Biol.
16,
3156-3168[Abstract]
|
| 33.
|
Yin, M. J.,
and Gaynor, R. B.
(1996)
J. Mol. Biol.
264,
20-31[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Zhao, L. J.,
and Giam, C. Z.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
11445-11449[Abstract/Free Full Text]
|
| 35.
|
Tang, Y.,
Tie, F.,
Boros, I.,
Harrod, R.,
Glover, M.,
and Giam, C. Z.
(1998)
J. Biol. Chem.
273,
27339-27346[Abstract/Free Full Text]
|
| 36.
|
Kimzey, A. L.,
and Dynan, W. S.
(1998)
J. Biol. Chem.
273,
13768-13775[Abstract/Free Full Text]
|
| 37.
|
Lenzmeir, B. A.,
Giebler, H. A.,
and Nyborg, J. K.
(1998)
Mol. Cell. Biol.
18,
721-731[Abstract/Free Full Text]
|
| 38.
|
Lundblad, J. R.,
Kwok, R. P.,
Laurance, M. E.,
Huang, M. S.,
Richards, J. P.,
Brennan, R. G.,
and Goodman, R. H.
(1998)
J. Biol. Chem.
273,
19251-19259[Abstract/Free Full Text]
|
| 39.
|
Kwok, R. P.,
Laurance, M. E.,
Lundblad, J. R.,
Goldman, P. S.,
Shih, H.,
Connor, L. M.,
Marriott, S. J.,
and Goodman, R. H.
(1996)
Nature
380,
642-646[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Harrod, R.,
Tang, Y.,
Nicot, C.,
Lu, H. S.,
Vassilev, A.,
Nakatani, Y.,
and Giam, C. Z.
(1998)
Mol. Cell. Biol.
18,
5052-5061[Abstract/Free Full Text]
|
| 41.
|
Deak, M.,
Clifton, A. D.,
Lucocq, L. M.,
and Alessi, D. R.
(1998)
EMBO J.
17,
4426-4441[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Gonzalez, G. A.,
and Montminy, M. R.
(1989)
Cell
59,
675-680[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Gonzalez, G. A.,
Yamamoto, K. K.,
Fischer, W. H.,
Karr, D.,
Menzel, P.,
Biggs, W.,
Vale, W. W.,
and Montminy, M. R.
(1989)
Nature
337,
749-752[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Matthews, R. P.,
Guthrie, C. R.,
Wailes, L. M.,
Zhao, X.,
Means, A. R.,
and McKnight, G. S.
(1994)
Mol. Cell. Biol.
14,
6107-6116[Abstract/Free Full Text]
|
| 45.
|
Giebler, H. A.,
Loring, J. E.,
van Orden, K.,
Colgin, M. A.,
Garrus, J. E.,
Escudero, K. W.,
Brauweiler, A.,
and Nyborg, J. K.
(1997)
Mol. Cell. Biol.
17,
5156-5164[Abstract]
|
| 46.
|
Yan, J. P.,
Garrus, J. E.,
Giebler, H. A.,
Stargall, L. A.,
and Nyborg, J. K.
(1998)
J. Mol. Biol.
281,
395-400[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Smith, M. R.,
and Greene, W. C.
(1990)
Genes Dev.
4,
1875-1885[Abstract/Free Full Text]
|
| 48.
|
Tie, F.,
Adya, N.,
Greene, W. C.,
and Giam, C. Z.
(1996)
J. Virol.
70,
8368-8374[Abstract]
|
| 49.
|
Giles, R. H.,
Peters, D. J.,
and Breuning, M. H.
(1998)
Trends Genet.
14,
178-183[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Imhof, A.,
Yang, X. J.,
Ogryzko, V. V.,
Nakatani, Y.,
Wolffe, A. P.,
and Ge, H.
(1997)
Curr. Biol.
7,
689-692[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Janknecht, R.,
and Hunter, T.
(1996)
Nature
383,
22-23[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Kwok, R. P.,
Lundblad, J. R.,
Chrivia, J. C.,
Richards, J. P.,
Bachinger, H. P.,
Brennan, R. G.,
Roberts, S. G.,
Green, M. R.,
and Goodman, R. H.
(1994)
Nature
370,
223-226[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Lundblad, J. R.,
Kwok, R. P.,
Laurance, M. E.,
Harter, M. L.,
and Goodman, R. H.
(1995)
Nature
374,
85-88[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Ogryzko, V. V.,
Schiltz, R. L.,
Russanova, V.,
Howard, B. H.,
and Nakatani, Y.
(1996)
Cell
87,
953-959[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Krumm, A.,
Madisen, L.,
Yang, X. J.,
Goodman, R.,
Nakatani, Y.,
and Groudine, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13501-13506[Abstract/Free Full Text]
|
| 56.
|
Xu, W.,
Edmondson, D. G.,
and Roth, S. Y.
(1998)
Mol. Cell. Biol.
18,
5659-5669[Abstract/Free Full Text]
|
| 57.
|
Yang, X. J.,
Ogryzko, V. V.,
Nishikawa, J.,
Howard, B. H.,
and Nakatani, Y.
(1996)
Nature
382,
319-324[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Schiltz, R. L.,
Mizzen, C. A.,
Vassilev, A.,
Cook, R. G.,
Allis, C. D.,
and Nakatani, Y.
(1999)
J. Biol. Chem.
274,
1189-1192[Abstract/Free Full Text]
|
| 59.
|
Korzus, E.,
Torchia, J.,
Rose, D. W.,
Xu, L.,
Kurokawa, R.,
McInerney, E. M.,
Mullen, T. M.,
Glass, C. K.,
and Rosenfeld, M. G.
(1998)
Science
279,
703-707[Abstract/Free Full Text]
|
| 60.
|
Kurokawa, R.,
Kalafus, D.,
Ogliastro, M. H.,
Kioussi, C.,
Xu, L.,
Torchia, J.,
Rosenfeld, M. G.,
and Glass, C. K.
(1998)
Science
279,
700-703[Abstract/Free Full Text]
|
| 61.
|
Puri, P. L.,
Sartorelli, V.,
Yang, X. J.,
Hamamori, Y.,
Ogryzko, V. V.,
Howard, B. H.,
Kedes, L.,
Wang, J. Y.,
Graessmann, A.,
Nakatani, Y.,
and Levrero, M.
(1997)
Mol. Cell
1,
35-45[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Arany, Z.,
Newsome, D.,
Oldread, E.,
Livingston, D. M.,
and Eckner, R.
(1995)
Nature
374,
81-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Chakravati, D.,
Ogryzko, V.,
Kao, H. Y.,
Nash, A.,
Chen, H.,
Nakatani, Y.,
and Evans, R. M.
(1999)
Cell
96,
393-403[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Hamamori, Y.,
Sartorelli, V.,
Ogryzko, V.,
Puri, P. L.,
Wu, H. Y.,
Wang, J. Y.,
Nakatani, Y.,
and Kedes, L.
(1999)
Cell
96,
405-413[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Perissi, V.,
Dasen, J. S.,
Kurokawa, R.,
Wang, Z.,
Korzus, E.,
Rose, D. W.,
Glass, C. K.,
and Rosenfeld, M. G.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3652-3657[Abstract/Free Full Text]
|
| 66.
|
Reid, J. L.,
Bannister, A. J.,
Zegerman, P.,
Martinez-Balbas, M. A.,
and Kouzarides, T.
(1998)
EMBO J.
17,
4469-4477[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Adya, N.,
and Giam, C. Z.
(1995)
J. Virol.
69,
1834-1841[Abstract]
|
| 68.
|
Nagata, K.,
Ohtani, K.,
Nakamura, M.,
and Sugamura, K.
(1989)
J. Virol.
63,
3220-3226[Abstract/Free Full Text]
|
| 69.
|
Cho, H.,
Orphanides, G.,
Sun, X.,
Yang, X. J.,
Ogryzko, V.,
Lees, E.,
Nakatani, Y.,
and Reinberg, D.
(1998)
Mol. Cell. Biol.
18,
5355-5363[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. C. Y. Ku, J. Lee, J. Lau, M. Gurumurthy, R. Ng, S. H. Lwa, J. Lee, Z. Klase, F. Kashanchi, and S.-H. Chao
XBP-1, a Novel Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Binding Protein, Activates HTLV-1 Basal and Tax-Activated Transcription
J. Virol.,
May 1, 2008;
82(9):
4343 - 4353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-K. Cho, M. Zhou, M. K. Jang, K. Huang, S.-J. Jeong, K. Ozato, and J. N. Brady
Modulation of the Brd4/P-TEFb Interaction by the Human T-Lymphotropic Virus Type 1 Tax Protein
J. Virol.,
October 15, 2007;
81(20):
11179 - 11186.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Sinha-Datta, A. Datta, S. Ghorbel, M. D. Dodon, and C. Nicot
Human T-cell Lymphotrophic Virus Type I Rex and p30 Interactions Govern the Switch between Virus Latency and Replication
J. Biol. Chem.,
May 11, 2007;
282(19):
14608 - 14615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-J. Jeong, H. Lu, W.-K. Cho, H. U. Park, C. Pise-Masison, and J. N. Brady
Coactivator-Associated Arginine Methyltransferase 1 Enhances Transcriptional Activity of the Human T-Cell Lymphotropic Virus Type 1 Long Terminal Repeat through Direct Interaction with Tax.
J. Virol.,
October 1, 2006;
80(20):
10036 - 10044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Zhang, M. Liu, R. Merling, and C.-Z. Giam
Versatile Reporter Systems Show that Transactivation by Human T-Cell Leukemia Virus Type 1 Tax Occurs Independently of Chromatin Remodeling Factor BRG1.
J. Virol.,
August 1, 2006;
80(15):
7459 - 7468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-T. Siu, K.-T. Chin, K.-L. Siu, E. Yee Wai Choy, K.-T. Jeang, and D.-Y. Jin
TORC1 and TORC2 Coactivators Are Required for Tax Activation of the Human T-Cell Leukemia Virus Type 1 Long Terminal Repeats
J. Virol.,
July 15, 2006;
80(14):
7052 - 7059.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Lemasson, N. J. Polakowski, P. J. Laybourn, and J. K. Nyborg
Tax-dependent Displacement of Nucleosomes during Transcriptional Activation of Human T-Cell Leukemia Virus Type 1
J. Biol. Chem.,
May 12, 2006;
281(19):
13075 - 13082.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Zhou, H. Lu, H. Park, J. Wilson-Chiru, R. Linton, and J. N. Brady
Tax Interacts with P-TEFb in a Novel Manner To Stimulate Human T-Lymphotropic Virus Type 1 Transcription.
J. Virol.,
May 1, 2006;
80(10):
4781 - 4791.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Tabakin-Fix, I. Azran, Y. Schavinky-Khrapunsky, O. Levy, and M. Aboud
Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications
Carcinogenesis,
April 1, 2006;
27(4):
673 - 681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Miyazato, S. Sheleg, H. Iha, Y. Li, and K.-T. Jeang
Evidence for NF-{kappa}B- and CBP-Independent Repression of p53's Transcriptional Activity by Human T-Cell Leukemia Virus Type 1 Tax in Mouse Embryo and Primary Human Fibroblasts
J. Virol.,
July 15, 2005;
79(14):
9346 - 9350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Awasthi, A. Sharma, K. Wong, J. Zhang, E. F. Matlock, L. Rogers, P. Motloch, S. Takemoto, H. Taguchi, M. D. Cole, et al.
A Human T-Cell Lymphotropic Virus Type 1 Enhancer of Myc Transforming Potential Stabilizes Myc-TIP60 Transcriptional Interactions
Mol. Cell. Biol.,
July 15, 2005;
25(14):
6178 - 6198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Forgacs, S. K. Gupta, J. A. Kerry, and O. J. Semmes
The bZIP Transcription Factor ATFx Binds Human T-Cell Leukemia Virus Type 1 (HTLV-1) Tax and Represses HTLV-1 Long Terminal Repeat-Mediated Transcription
J. Virol.,
June 1, 2005;
79(11):
6932 - 6939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Wong, A. Sharma, S. Awasthi, E. F. Matlock, L. Rogers, C. Van Lint, D. J. Skiest, D. K. Burns, and R. Harrod
HIV-1 Tat Interactions with p300 and PCAF Transcriptional Coactivators Inhibit Histone Acetylation and Neurotrophin Signaling through CREB
J. Biol. Chem.,
March 11, 2005;
280(10):
9390 - 9399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Wong, J. Zhang, S. Awasthi, A. Sharma, L. Rogers, E. F. Matlock, C. Van Lint, T. Karpova, J. McNally, and R. Harrod
Nerve Growth Factor Receptor Signaling Induces Histone Acetyltransferase Domain-dependent Nuclear Translocation of p300/CREB-binding Protein-associated Factor and hGCN5 Acetyltransferases
J. Biol. Chem.,
December 31, 2004;
279(53):
55667 - 55674.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Calomme, A. Dekoninck, S. Nizet, E. Adam, T. L.-A. Nguyen, A. Van Den Broeke, L. Willems, R. Kettmann, A. Burny, and C. Van Lint
Overlapping CRE and E Box Motifs in the Enhancer Sequences of the Bovine Leukemia Virus 5' Long Terminal Repeat Are Critical for Basal and Acetylation-Dependent Transcriptional Activity of the Viral Promoter: Implications for Viral Latency
J. Virol.,
December 15, 2004;
78(24):
13848 - 13864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lu, C. A. Pise-Masison, R. Linton, H. U. Park, R. L. Schiltz, V. Sartorelli, and J. N. Brady
Tax Relieves Transcriptional Repression by Promoting Histone Deacetylase 1 Release from the Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat
J. Virol.,
July 1, 2004;
78(13):
6735 - 6743.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Casoli, A. De Lerma Barbaro, E. Pilotti, U. Bertazzoni, G. Tosi, and R. S. Accolla
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2
Blood,
February 1, 2004;
103(3):
995 - 1001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. D. Motton and G. C. Buehring
Bovine Leukemia Virus Alters Growth Properties and Casein Synthesis in Mammary Epithelial Cells
J Dairy Sci,
September 1, 2003;
86(9):
2826 - 2838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Georges, H. A. Giebler, P. A. Cole, K. Luger, P. J. Laybourn, and J. K. Nyborg
Tax Recruitment of CBP/p300, via the KIX Domain, Reveals a Potent Requirement for Acetyltransferase Activity That Is Chromatin Dependent and Histone Tail Independent
Mol. Cell. Biol.,
May 15, 2003;
23(10):
3392 - 3404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.-X. Fu, Y.-L. Kuo, B.-Y. Liu, K.-T. Jeang, and C.-Z. Giam
Human T-lymphotropic Virus Type I Tax Activates I-kappa B Kinase by Inhibiting I-kappa B Kinase-associated Serine/Threonine Protein Phosphatase 2A
J. Biol. Chem.,
January 10, 2003;
278(3):
1487 - 1493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Lemasson, N. J. Polakowski, P. J. Laybourn, and J. K. Nyborg
Transcription Factor Binding and Histone Modifications on the Integrated Proviral Promoter in Human T-cell Leukemia Virus-I-infected T-cells
J. Biol. Chem.,
December 13, 2002;
277(51):
49459 - 49465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Okada and K.-T. Jeang
Differential Requirements for Activation of Integrated and Transiently Transfected Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat
J. Virol.,
November 13, 2002;
76(24):
12564 - 12573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lu, C. A. Pise-Masison, T. M. Fletcher, R. L. Schiltz, A. K. Nagaich, M. Radonovich, G. Hager, P. A. Cole, and J. N. Brady
Acetylation of Nucleosomal Histones by p300 Facilitates Transcription from Tax-Responsive Human T-Cell Leukemia Virus Type 1 Chromatin Template
Mol. Cell. Biol.,
July 1, 2002;
22(13):
4450 - 4462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Merezak, M. Reichert, C. Van Lint, P. Kerkhofs, D. Portetelle, L. Willems, and R. Kettmann
Inhibition of Histone Deacetylases Induces Bovine Leukemia Virus Expression In Vitro and In Vivo
J. Virol.,
April 16, 2002;
76(10):
5034 - 5042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-H. Liang, T. Geisbert, Y. Yao, S. H. Hinrichs, and C.-Z. Giam
Human T-Lymphotropic Virus Type 1 Oncoprotein Tax Promotes S-Phase Entry but Blocks Mitosis
J. Virol.,
March 19, 2002;
76(8):
4022 - 4033.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. L. Van, K.-W. Yim, D.-Y. Jin, G. Dapolito, A. Kurimasa, and K.-T. Jeang
Genetic Evidence of a Role for ATM in Functional Interaction between Human T-Cell Leukemia Virus Type 1 Tax and p53
J. Virol.,
January 1, 2001;
75(1):
396 - 407.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. Nicot and R. Harrod
Distinct p300-Responsive Mechanisms Promote Caspase-Dependent Apoptosis by Human T-Cell Lymphotropic Virus Type 1 Tax Protein
Mol. Cell. Biol.,
November 15, 2000;
20(22):
8580 - 8589.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. A. Pise-Masison, R. Mahieux, M. Radonovich, H. Jiang, and J. N. Brady
Human T-lymphotropic Virus Type I Tax Protein Utilizes Distinct Pathways for p53 Inhibition That Are Cell Type-dependent
J. Biol. Chem.,
January 5, 2001;
276(1):
200 - 205.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|